2021 Pipeline Insights on Vestibular Schwannoma – Featuring AstraZeneca, Recursion Pharmaceuticals and Takeda Among…

first_img Twitter Pinterest WhatsApp Facebook Twitter 2021 Pipeline Insights on Vestibular Schwannoma – Featuring AstraZeneca, Recursion Pharmaceuticals and Takeda Among Others – ResearchAndMarkets.com How many companies are developing Vestibular Schwannoma drugs?How many Vestibular Schwannoma drugs are developed by each company?How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Vestibular Schwannoma?What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Vestibular Schwannoma therapeutics?What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?What are the clinical studies going on for Vestibular Schwannoma and their status?What are the key designations that have been granted to the emerging drugs? Key PlayersAstraZenecaRecursion PharmaceuticalsTakedaGenentech For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/8enmkv View source version on businesswire.com:https://www.businesswire.com/news/home/20210204005699/en/ CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 KEYWORD: INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY SOURCE: Research and Markets Copyright Business Wire 2021. PUB: 02/04/2021 08:56 AM/DISC: 02/04/2021 08:56 AM http://www.businesswire.com/news/home/20210204005699/en DUBLIN–(BUSINESS WIRE)–Feb 4, 2021– The “Vestibular Schwannoma – Pipeline Insight, 2021” drug pipelines has been added to ResearchAndMarkets.com’s offering. This report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Vestibular Schwannoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Unilateral/asymmetric hearing loss and/or tinnitus and loss of balance/dizziness are early signs of a vestibular schwannoma. Unfortunately, early detection of the tumor is sometimes difficult because the symptoms may be subtle and may not appear in the beginning stages of growth. Once the symptoms appear, a thorough ear examination and hearing and balance testing (audiogram, electronystagmography, and auditory brainstem responses) are essential for proper diagnosis. Magnetic resonance imaging (MRI) scans are critical in the early detection of a vestibular schwannoma and are helpful in determining the location and size of a tumor and in planning its microsurgical removal. Treatment There are three options for managing a vestibular schwannoma: (1) surgical removal, (2) radiation, and (3) observation. Sometimes, the tumor is surgically removed (excised). The exact type of operation done depends on the size of the tumor and the level of hearing in the affected ear. If the tumor is small, hearing may be saved and accompanying symptoms may improve by removing it to prevent its eventual effect on the hearing nerve. As the tumor grows larger, surgical removal is more complicated because the tumor may have damaged the nerves that control facial movement, hearing, and balance and may also have affected other nerves and structures of the brain. As an alternative to conventional surgical techniques, radiosurgery (that is, radiation therapy – the “gamma knife” or LINAC) may be used to reduce the size or limit the growth of the tumor. Radiation therapy is sometimes the preferred option for elderly patients, patients in poor medical health, patients with bilateral vestibular schwannoma (tumor affecting both ears), or patients whose tumor is affecting their only hearing ear. Vestibular Schwannoma Emerging Drugs Chapters This segment of the Vestibular Schwannoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases. Vestibular Schwannoma Emerging Drugs Selumetinib: AstraZeneca Selumetinib is being developed by AstraZeneca for the treatment of vestibular schwannoma and is currently in Phase 2 trial of clinical study. It acts MAP Kinase 1 inhibitors and MAP Kinase 2 inhibitors. The Phase 2 trial got initiated in May 2017 and is expected to get completed by May 2022 with estimated 34 enrolled participants. Vestibular Schwannoma: Therapeutic Assessment This segment of the report provides insights about the different Vestibular Schwannoma drugs segregated based on following parameters that define the scope of the report, such as: Major Players in Vestibular Schwannoma There are approx. 10+ key companies which are developing the therapies for Vestibular Schwannoma. The companies which have their Vestibular Schwannoma drug candidates in the most advanced stage, i. e. phase II include, AstraZeneca. Phases This report covers around 10+ products under different phases of clinical development likeLate stage products (Phase III)Mid-stage products (Phase II)Early-stage product (Phase I) along with the details ofPre-clinical and Discovery stage candidatesDiscontinued & Inactive candidatesRoute of Administration Vestibular Schwannoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such asOralParenteralintravitrealSubretinalTopical.Molecule Type Products have been categorized under various Molecule types such asMonoclonal AntibodyPeptidesPolymerSmall moleculeGene therapyProduct Type Vestibular Schwannoma: Pipeline Development Activities The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Vestibular Schwannoma therapeutic drugs key players involved in developing key drugs. Pipeline Development Activities The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Vestibular Schwannoma drugs. Report HighlightsThe companies and academics are working to assess challenges and seek opportunities that could influence Vestibular Schwannoma R&D. The therapies under development are focused on novel approaches to treat/improve Vestibular Schwannoma. Vestibular Schwannoma Report InsightsVestibular Schwannoma Pipeline AnalysisTherapeutic AssessmentUnmet NeedsImpact of Drugs Vestibular Schwannoma Report AssessmentPipeline Product ProfilesTherapeutic AssessmentPipeline AssessmentInactive drugs assessmentUnmet Needs Key Questions Answered Current Treatment Scenario and Emerging Therapies: Facebook TAGS  Local NewsBusiness By Digital AIM Web Support – February 4, 2021 Pinterest WhatsApp Previous articleAdvent Technologies Inc. and AMCI Acquisition Corp. Announce Closing of Business CombinationNext articleAppSec Market Leader Veracode Continues Strong Growth and Business Momentum Digital AIM Web Supportlast_img read more